AOD-9604 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-08-26 and is reviewed periodically as new material appears.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
=== Reproduction studies === Patulin decreased sperm count and altered sperm morphology in the rat. Also, it resulted in abortion of F1 litters in rats and mice after i.p. injection. Embryotoxicity and teratogenicity were also reported in chick eggs.
== External links == Insulin-Like+Growth+Factor+I at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Overview of all the structural information available in the PDB for UniProt: P05019 (Insulin-like growth factor I) at the PDBe-KB.
Since the ligand is responsible for cellular interaction, it is chosen for the application depending on the target site. The target site contains binding sites that the ligand targets to deliver the LTL to the desired area. Favorable target site characteristics are determined by what is commonly expressed by tissues of the pathology of interest. Determinants can include histones, basement membrane fibrinogen, selectins, adhesion molecules, and other ligand targets. For example, in some human cancer tumors such as ovarian carcinomas, folate is over-expressed. LTLs for targeting cancer often use a ligand that targets this over-expression of folate to localize drug delivery to the desired area. The tumor microenvironment of solid tumor cancers is also a unique targeting site. Tumor endothelial cells are important for angiogenesis, which is key to tumor growth; therefore, using LTLs to target these cells can limit the growth and vascularization of a tumor.
Solid-state diffusion is the net movement of atoms in solid phase, from a region of higher concentration to one of lower concentration. It is easy to imagine diffusion in a liquid phase as ink spreading in water. Solid-state diffusion of Pb is the net exchange of Pb in the solid mineral with the external environment, which is usually a fluid. In most of the cases, Pb is transported from the mineral to the fluid, resulting in Pb loss and thus age resetting. The rate of diffusion increases with temperature as atoms are moving faster. However, as the mineral cools and the crystal structure becomes more complete, the diffusions of parent and daughter isotopes slow down and finally become insignificant at a certain temperature. This closure temperature (Tc) depends on the crystal size, shape, cooling rate and diffusion coefficient, which in turn varies for each mineral and radioactive systems. That is, above Tc, Pb is continuously lost and the radioactive clock is keeping zero. Once the temperature falls below Tc, the system is closed and the clock starts counting. Monazite is characterized by its high Pb retention ability even at high temperatures for a prolonged period. The closure temperature of monazite in U-Th-Pb system is higher than 800 °C, much higher than the other common minerals.
Sources: en.wikipedia.org
Combining these alongside psychotherapies like CBT may lead to better outcomes for BED. GLP-1 receptor agonist medications such as semaglutide (Ozempic), dulaglutide (Trulicity), and liraglutide (Saxenda) have been used for treating BED in recent years. Often prescribed for lowering appetite and subsequent weight loss in people with diabetes mellitus and obesity, they can successfully stop or reduce obsessive thoughts about food, binging urges, and other impulsive behaviors. Some users, reported sudden improvement in "food noise" - constant unstoppable thoughts about food, even not being physically hungry, which can be a symptom of BED. To this promising treatment is on the up for success, but additional research is needed as of January 2024.
Partition chromatography is a specific form of column chromatography, specialized for separating analytes with only slight differences in partition coefficients between two liquid solvents. The solid phase in the chromatography column consists of particles coated with one liquid solvent, and the other liquid solvent acts as the eluent. Its theory and practice was introduced through the work and publications of Archer Martin and Richard Laurence Millington Synge during the 1940s. They would later receive the 1952 Nobel Prize in Chemistry "for their invention of partition chromatography".
Proton donors and acceptors, i.e. acids and base may donate and accept protons in order to stabilize developing charges in the transition state. This is related to the overall principle of catalysis, that of reducing energy barriers, since in general transition states are high energy states, and by stabilizing them this high energy is reduced, lowering the barrier. A key feature of enzyme catalysis over many non-biological catalysis, is that both acid and base catalysis can be combined in the same reaction. In many abiotic systems, acids (large [H+]) or bases ( large concentration H+ sinks, or species with electron pairs) can increase the rate of the reaction; but of course the environment can only have one overall pH (measure of acidity or basicity (alkalinity)). However, since enzymes are large molecules, they can position both acid groups and basic groups in their active site to interact with their substrates, and employ both modes independent of the bulk pH. Often general acid or base catalysis is employed to activate nucleophile and/or electrophile groups, or to stabilize leaving groups. Many amino acids with acidic or basic groups are this employed in the active site, such as the glutamic and aspartic acid, histidine, cystine, tyrosine, lysine and arginine, as well as serine and threonine. In addition, the peptide backbone, with carbonyl and amide N groups is often employed. Cystine and Histidine are very commonly involved, since they both have a pKa close to neutral pH and can therefore both accept and donate protons.
Sources: en.wikipedia.org
== Cause == PMOS's root cause is unknown. Risk factors include a family history of PMOS, early development of pubic hair and sweat gland development (adrenarche), and obesity. Low birth weight, exposure to androgens in the womb, and exposure to hormone disruptors may also predispose people to PMOS.
In 1943, Glaxo was responsible for 2,570 million of the 3,500 million Oxford units produced in the UK. Glaxo opened a third factory at Watford in February 1944 and a fourth at Stratford, London, in January 1945. The company was responsible for 80 per cent of the UK's output up to June 1944. In 1944 the Ministry of Supply arranged for the Commercial Solvents Company to install the first deep submergence plant at Speke, and it asked Glaxo to build one too. This new Glaxo plant opened at Barnard Castle in January 1946 and produced more penicillin over the next nine months than its surface plants had produced in all of 1945. The surface plants were all closed in 1946. Penicillin production in the UK increased from 25 million units per week in March 1943 to 30 billion per week in 1946.
Reducing information asymmetry: Price information affects competitive markets' efficiency because it impacts price dispersion, arbitrage, and farmer and consumer welfare. Since the marginal cost of digitally delivering information approaches zero, digital agriculture has the potential to spread price information. Aker and Fafchamps find that the introduction of mobile phone coverage in Niger reduced spatial price dispersion for agri-food products, especially for remote markets and perishable goods. Similarly, price information provided by Internet kiosks ("e-choupals") in India led to an increase in farmers' net profits as traders lost monopsony power. Other examples of digital platforms for price information include MFarm and Esoko. Matching buyers and sellers: E-commerce lowers the search costs of matching buyers and sellers, potentially shortening the value chain. Rather than go through dozens of intermediaries, farmers can sell directly to consumers. Market access services can also solve the matching problem without necessarily hosting online transactions. For example, Esoko sends market information (prices for specific commodities, market locations, etc.) to agents and farmers, connecting them to commodity buyers. All of these matching platforms help smallholders coordinate with buyers and enter both regional and global value chains. Finally, digital technologies can also facilitate matching in financial and input markets, not just producer-to-consumer output sales.
== Biology == The 7kDa proteins are universally found in Sulfolobus, where two copies (Sul7d, Sul7e) are present as separate genes. The proteins are usually named after the species, e.g. Sso7d for the 7d of S. solfataricus and Sac7e for the 7e of S. acidocaldarius. Sul7a and Sul7b are truncated versions of 7d. "Sso7c" does not appear to be a member of this family. S. tokodaii is unusual in that the two copies only differ by one nucleotide and produce the same protein, so its version is simply called Sto7. Across Sulfolobales, Acidianus, Metallosphaera, and "Candidatus Aramenus" also encode a 7kDa DNA-binding protein, named according to the genus name or the species name in an analogous fashion. Each genome may carry anywhere from 1 to 3 versions of the protein.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.